Abstract:The orphan G protein-coupled receptor GPR55 has been proposed as a new potential drug target for the treatment of diabetes, Parkinson's disease, neuropathic pain, and cancer. Coumarin and 8-amido-chromen-4-one-2-carboxylic acid derivatives were identified as novel antagonists for GPR55. In this study, we established reliable models and explored the valuable information by quantitative structure–activity relationship (QSAR). Firstly, we obtained a quite reliable multiple linear regression (MLR) model with correlation coefficient (R2) of 0.8204 for the training set, and R2 of 0.7770 for the test set. Next, we built a better model with R2 of 0.8763 for the training set, and R2 of 0.8179 for the test set based on the simplified molecular input line entry system (SMILES). Lastly, we established dependable comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) models. Then we validated these models' predictive ability using various validation methods for the test set. Besides, we designed and confirmed six new potential inhibitors with higher predicted activities and tested twenty-eight compounds without clear activities by the established models. The results obtained from molecular modeling not only provide models to predict the activities of inhibitors but also lead to a better understanding of the essential features that should be considered when designing novel inhibitors with desired activities.

Structure-Activity Relationship Studies of Coumarin-like Diacid Derivatives As Human G Protein-Coupled Receptor-35 (hgpr35) Agonists and a Consequent New Design Principle.

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Discovery of 2H-Chromen-2-one Derivatives As G Protein-Coupled Receptor-35 Agonists

Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists.

Synthesis and Biological Evaluation of 1, 2, 4-Oxadiazole Derivatives As Novel Gpr119 Agonists

Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.

SAR Studies of N-[2-(1H-Tetrazol-5-yl)phenyl]benzamide Derivatives As Potent G Protein-Coupled Receptor-35 Agonists.

Structure-activity relationship studies of tetrahydroquinolone derivatives as GPR41 modulators

Discovery of (S)-3-(4-(benzyloxy)phenyl)-2-(2-phenoxyacetamido)propanoic Acid Derivatives As a New Class of GPR34 Antagonists.

Synthesis and Evaluation of Novel Fused Pyrimidine Derivatives As GPR119 Agonists.

3D-QSAR and Molecular Docking Studies of Novel GPR52 Agonists

Design and Biological Evaluation of Tetrahydropyridine Derivatives As Novel Human GPR119 Agonists

Design and Synthesis of 2-Alkylpyrimidine-4,6-diol and 6-Alkylpyridine-2,4-diol As Potent GPR84 Agonists.

Identification of Spiro[chromene-2,4'-piperidine]s As Potent, Selective, and Gq-Biased 5-HT2C Receptor Partial Agonists.

Discovery, Cocrystallization and Biological Evaluation of Novel Piperidine Derivatives As High Affinity Ls-AChBP Ligands Possessing Α7 Nachr Activities.

Structural Optimizations and Bioevaluation of N-H Aporphine Analogues As Gq-biased and Selective Serotonin 5-HT2C Receptor Agonists.

Study on the antagonists for the orphan G protein-coupled receptor GPR55 by quantitative structure–activity relationship

Rational Design, Synthesis, Biological Evaluation, Homology and Docking Studies of Coumarin Derivatives As Α1 -Adrenoceptor Antagonists.

Pyrazolidine-3,5-dione Derivatives As Potent Non-Steroidal Agonists of Farnesoid X Receptor: Virtual Screening, Synthesis, and Biological Evaluation.

Sulfoxide Analogs of Tak-875 As G Protein Coupled Receptor 40 Agonists: Synthesis, Determination of Absolute Configuration and Biological Activity

Synthesis, Crystal Structure, Biological Evaluation, and Molecular Docking Studies of Quinoline-Arylpiperazine Derivative As Potent Α1a-Adrenoceptor Antagonist